Drugmakers race to bring new cholesterol drugs to US market

New York

REGENERON Pharmaceuticals Inc and Sanofi may get a head start on their biggest competitor in bringing a new class of cholesterol drugs to the US market.

The US Food and Drug Administration (FDA) has until July 24 to make a decision on the companies' application to market their jointly developed drug alirocumab, Regeneron and Sanofi said in a statement.